Skip to Content

Humira FDA Approval History

FDA Approved: Yes (First approved December 31, 2002)
Brand name: Humira
Generic name: adalimumab
Dosage form: Injection
Company: AbbVie Inc.
Treatment for: Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Acute, Crohn's Disease, Maintenance, Psoriasis, Juvenile Idiopathic Arthritis, Ulcerative Colitis, Hidradenitis Suppurativa, Uveitis

Humira (adalimumab) is a recombinant human IgGl monoclonal antibody specific for human tumor necrosis factor (TNF) indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, juvenile idiopathic arthritis, ulcerative colitis, hidradenitis suppurativa, and certain types of uveitis.

Development Timeline for Humira

Mar 30, 2017ApprovalFDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's Humira (adalimumab) Prescribing Information
Jun 30, 2016ApprovalAbbVie's Humira (adalimumab) Receives FDA Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis
Sep 11, 2015ApprovalFDA Approves Humira (adalimumab) for Moderate to Severe Hidradenitis Suppurativa
Sep 25, 2014ApprovalFDA Approves Humira (adalimumab) for the Treatment of Pediatric Patients with Crohn's Disease
Sep 28, 2012ApprovalFDA Approves Humira to Treat Ulcerative Colitis
Feb 22, 2008ApprovalAbbott Receives FDA Approval for Humira (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Jan 22, 2008ApprovalAbbott's Humira (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Feb 27, 2007ApprovalHumira (Adalimumab) Receives FDA Approval For Treatment of Crohn'sDisease
Jul 31, 2006ApprovalHumira Receives FDA Approval for Treatment of Ankylosing Spondylitis
Oct  4, 2005ApprovalHumira Receives FDA Approval for Psoriatic Arthritis
Dec 31, 2002ApprovalFDA Approves Humira (adalimumab) for Rheumatoid Arthritis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.